Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults
about
Safety of human papillomavirus vaccines: a review.Towards the eradication of HPV infection through universal specific vaccination.Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.Dominant role of HPV16 E7 in anal carcinogenesis.Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old[Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis].Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trialsComprehensive clinical care for men who have sex with men: an integrated approach.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.[HPV-vaccination - not just for girls].
P2860
Q33162724-C8C2F6D9-43D2-4DE7-9028-3DFF134AF673Q34812959-A140EEF7-8E5E-4C92-A9DD-C18CAB555C36Q35210878-5C8D5032-3245-4495-AF27-D3A0A878D651Q35673591-0E13F28B-19E9-4D96-9F45-C841D4D6BA09Q35739048-F71C934B-4677-4478-8322-6A570C202BB8Q36388694-906F0FBA-FAEF-4FCC-B90F-0288DE3A07C0Q37130168-07D3331C-F6E0-450B-9554-050E75461DC5Q37425284-6FB600DB-EE49-40CD-A5EF-A5337C7B743AQ38028184-EB347674-B76C-4302-8FF0-3BB1C108C40BQ38229304-2F3C0859-5EE9-4527-A7B8-D767C4D582B9Q38370782-4F6C8C00-059D-46B6-A633-5199418D4A76Q40179042-5F69E2E8-F502-4D81-AA24-441AE22DD6D1Q41201908-658BFE28-F35C-4D50-85F1-81154CCC0719
P2860
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and reactogenicity of a ...... r adolescents and young adults
@ast
Safety and reactogenicity of a ...... r adolescents and young adults
@en
type
label
Safety and reactogenicity of a ...... r adolescents and young adults
@ast
Safety and reactogenicity of a ...... r adolescents and young adults
@en
prefLabel
Safety and reactogenicity of a ...... r adolescents and young adults
@ast
Safety and reactogenicity of a ...... r adolescents and young adults
@en
P2093
P2860
P356
P1433
P1476
Safety and reactogenicity of a ...... r adolescents and young adults
@en
P2093
Anna R Giuliano
Carlos Aranda
Dalya Guris
Daron Ferris
Elizabeth I O Garner
Francois Coutlee
Heiko Jessen
J Brooke Marshall
Joel M Palefsky
Richard J Hillman
P2860
P304
P356
10.4161/HV.7.7.15579
P577
2011-07-01T00:00:00Z